GGrantIndex
← Search

Leukemia Tissue Bank

$59,639P30FY2007CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

The ability to successfully translate basic research in leukemia to the clinical setting, as well as to better understand the relevance of observed clinical phenomena through laboratory-based research, is greatly facilitated by the availability of an extensive repository of tissue samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR), separate and distinct from the CALGB Leukemia Tissue Bank, is a shared resource established in 1997 with over 4,500 patient samples procured from 762 consented leukemia patients at OSU. The infrastructure of the OSUCCC LTBSR is well-established and is directly under our leadership. Specifically we have a large leukemia tissue repository, including both leukemic tissue and normal tissue germ line DNA, accompanied in all cases with complete pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. In addition, all the essentials of effective leukemia tissue bank management, including the activities of tissue collection, quality control of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical information, data entry and database management, and patient consent and confidentiality are very well developed. Furthermore, the procedures for prioritizing and distributing tissue to a large base of investigators within the OUCCC are effectively in place. Finally, our success in managing this large leukemia tissue resource can be seen in the documented sample collection for and sample distribution to all leukemia researchers within the CCC and 28 publications where the OSUCCC LTBSR has played a significant role. Against this background, we believe that this Shared Resource will function well in the support of the research mission of the OSUCCC in )roducing high-quality basic and clinical research in hematological malignancy. Currently the OSUCCC _TBSR is funded solely with OSUCCC/institutional support. The Specific Aims of this Shared Resource are, therefore, to: 1) Continue to provide a central collection, processing and a state-of-the-art repository for samples collected from leukemia patients treated on OSU protocols, and 2) Provide materials from the LTBSR to interested investigators within OSUCCC, as well as to outside interested investigators involved in collaborative studies with OSU, who examine relevant cellular and molecular properties of leukemia.

View original record on NIH RePORTER →